The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Published version of a preprint
Abstract
p53 is a critical tumor suppressor and is the most frequently inactivated gene in human cancer. Inhibition of the interaction of p53 with its negative regulator MDM2 represents a promising clinical strategy to treat p53 wild-type tumors. AMG 232 is a potential best-in-class inhibitor of the MDM2–p53 interaction and is currently in clinical trials. We characterized the activity of AMG 232 and its effect on p53 signaling in several preclinical tumor models. AMG 232 binds the MDM2 protein with picomolar affinity and robustly induces p53 activity, leading to cell-cycle arrest and inhibition of tumor cell proliferation. AMG 232 treatment inhibited the in vivo growth of several tumor xenografts and led to complete and durable regression of MDM2-amplified SJSA-1 tumors via growth arrest and induction of apoptosis. Therapeutic combination studies of AMG 232 with chemotherapies that induce DNA damage and p53 activity resulted in significantly superior antitumor efficacy and regression, and markedly increased activation of p53 signaling in tumors. These preclinical data support the further evaluation of AMG 232 in clinical trials as both a monotherapy and in combination with standard-of-care cytotoxics. Mol Cancer Ther; 14(3); 649–58. ©2015 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, AMG232 is the most potent MDM2 inhibitor described to date [115].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [115]
In the citing paper
“Although a limitation is the differing subcutaneous tumor microenvironment, there is strong evidence that the cytotoxicity of MDM2 inhibitors is largely tumor cell autonomous (39, 40).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [39]
In the citing paper
“Similar results were observed in xenografts derived from non-GBM cancer cell lines (39).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [39]
In the citing paper
“AMG-232 (144) is a potent and highly selective oral piperidone inhibitor of MDM2-p53 interaction, with an IC50 of 0.6 nM and MDM2-binding Kd of 0.045 nM.383,384”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [383]
In the citing paper
“AMG232 can be combined with other cytotoxic drugs to improve its anti-tumor activity without obvious side effects [56].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [56]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Approximately 50% of human tumors harbor a mutated TP53 gene (3).”
BackgroundThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,451
Self-citationRegulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
The genetics of the p53 pathway, apoptosis and cancer therapy
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 676
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Cited by
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
“Among these, AMG232 is the most potent MDM2 inhibitor described to date [115].”
BackgroundRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Metadata
- Authors
- Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., Zhou, J., Cordover, D., Kaufman, S., Kendall, R., Oliner, J. D., Coxon, A., & Radinsky, R.
- Affiliations
- Amgen (United States) (US)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-03-01
- Volume
- 14
- Issue
- 3
- Pages
- 649-658
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2094916879
- Cited by
- 152
- References
- 18
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 14 · 2023: 15 · 2022: 19 · 2021: 24 · 2020: 14 · 2019: 13 · 2018: 12 · 2017: 4 · 2016: 13 · 2015: 2
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- MDM2 inhibitors, p53 activation, p53-MDM2 interaction, combination chemotherapy, DNA damage, cell cycle arrest, apoptosis, tumor xenografts, MDM2 amplification, antitumor efficacy
- MeSH terms
- Acetates, Animals, Antineoplastic Agents, Cytotoxins, Female, Humans, Mice, Nude, Piperidones, Tumor Suppressor Protein p53, Apoptosis, HT29 Cells, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2, Cell Cycle Checkpoints, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0710
- The paper
- Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., Zhou, J., Cordover, D., Kaufman, S., Kendall, R., Oliner, J. D., Coxon, A., & Radinsky, R. (2015). The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.